219 related articles for article (PubMed ID: 26923095)
1. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories.
Arthur R; Møller H; Garmo H; Holmberg L; Stattin P; Malmstrom H; Lambe M; Hammar N; Walldius G; Robinson D; Jungner I; Hemelrijck MV
Cancer Med; 2016 Jun; 5(6):1307-18. PubMed ID: 26923095
[TBL] [Abstract][Full Text] [Related]
2. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
[TBL] [Abstract][Full Text] [Related]
3. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
Arthur R; Williams R; Garmo H; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinsson D; Jungner I; Van Hemelrijck M
Int J Cancer; 2018 Jun; 142(11):2254-2262. PubMed ID: 29322512
[TBL] [Abstract][Full Text] [Related]
4. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.
Arthur R; Møller H; Garmo H; Häggström C; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinson D; Jungner I; Van Hemelrijck M
Cancer Causes Control; 2019 Feb; 30(2):195-206. PubMed ID: 30421156
[TBL] [Abstract][Full Text] [Related]
5. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
6. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.
Bosco C; Garmo H; Hammar N; Walldius G; Jungner I; Malmström H; Holmberg L; Van Hemelrijck M
BMC Cancer; 2018 Feb; 18(1):205. PubMed ID: 29463235
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
8. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.
Rantaniemi L; Tammela TLJ; Kujala P; Murtola TJ
Scand J Urol; 2018 Aug; 52(4):269-276. PubMed ID: 30362865
[TBL] [Abstract][Full Text] [Related]
9. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.
Van Hemelrijck M; Walldius G; Jungner I; Hammar N; Garmo H; Binda E; Hayday A; Lambe M; Holmberg L
Cancer Causes Control; 2011 Jul; 22(7):1011-9. PubMed ID: 21562751
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.
Van Hemelrijck M; Garmo H; Holmberg L; Walldius G; Jungner I; Hammar N; Lambe M
Cancer; 2011 May; 117(10):2086-95. PubMed ID: 21523720
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.
Jamnagerwalla J; Howard LE; Allott EH; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freeman MR; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):252-259. PubMed ID: 29282360
[TBL] [Abstract][Full Text] [Related]
14. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.
Melvin JC; Garmo H; Holmberg L; Hammar N; Walldius G; Jungner I; Lambe M; Van Hemelrijck M
BMC Cancer; 2017 Apr; 17(1):246. PubMed ID: 28376727
[TBL] [Abstract][Full Text] [Related]
15. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
16. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
18. High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer.
Wang FM; Zhang Y
Dis Markers; 2019; 2019():9483935. PubMed ID: 31885745
[TBL] [Abstract][Full Text] [Related]
19. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
20. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
